Natural products in the predatory defence of the filamentous fungal pathogen Aspergillus fumigatus

• Jana M. Boysen,
• Nauman Saeed and
• Falk Hillmann

Beilstein J. Org. Chem. 2021, 17, 1814–1827, doi:10.3762/bjoc.17.124

• foundation to understand its role in invasive aspergillosis [113]. In A. fumigatus 13 genes form a 28 kb biosynthetic cluster of gliotoxin, of which gliZ (a zinc-finger transcription factor) and gliP (an NRPS) together with global regulator LaeA regulate its expression at the genomic level [112][114][115

Advances in synthetic approach to and antifungal activity of triazoles

• Kumari Shalini,
• Nitin Kumar,
• Sushma Drabu and
• Pramod Kumar Sharma

Beilstein J. Org. Chem. 2011, 7, 668–677, doi:10.3762/bjoc.7.79

• exhibit a broad spectrum of pharmacological activity such as antifungal, antibacterial, anti-inflammatory and anticancer etc. Triazoles have increased our ability to treat many fungal infections, for example, candidiasis, cryptococcal meningitis, aspergillosis etc. However, mortality due to these

• we are entering a new era of antifungal therapy in which we will continue to be challenged by systemic fungal diseases, the options for treatment will have greatly expanded. Keywords: antifungal; aspergillosis; candidiasis; cryptococcal meningitis; triazole; Review Introduction The alarming rates

• produced which is excreted in faeces; t1/2 = 30–64 h [42]. Second generation of triazoles Voriconazole Voriconazole (11, Figure 10) was first marketed in 2002 and approved as a first-line treatment of oesophageal candidiasis, candidaemia, invasive aspergillosis, Candida infections of the skin, infections